Last month, I wrote a posting called "When Transparency is Easy -Advisory Committee Transparency" suggesting that the transparency at FDA would be greatly enhanced if there were once again links from the rosters of advisory committee members to their CVs. Such links used to be common place, now they are only in place for about half of CDER's committee membership. Once I posted this, one reader made a comment that I should leave the information as a comment to the FDA's Transparency Blog. I thought that a good idea.
About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.Stay Connected
My Profile
I am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
Twitter List
Legislative Tracking Tools
So how about some follow-up on why your comment was not posted? Is there a webmaster or moderator who can comment on how comments are selected and why yours wasn’t? Is the website really a place for transparency, or only the illusion of transparency that serves the interests of some FDA communications manager?
Mark, your comment dated July 17 on the FDA blog regarding the people on advisory committees is actually posted there, please look at http://fdatransparencyblog.fda.gov/2009/07/how-can-fda-use-its-website-to-improve-transparency-at-the-agency.html?cid=6a00e0097fa000883301157212c14c970b#comment-6a00e0097fa000883301157212c14c970b
Thank you so much for pointing it out. The last time I had checked in
August, it had not been posted, despite the fact that other comments made
subsequently had been. Appreciate the head’s up.
On Tue, Sep 15, 2009 at 9:51 PM, wrote: